Actualizado 09/09/2008 14:32
- Comunicado -

New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment (y 3)

(7) International Diabetes Federation, Global Guidelines for Type 2 Diabetes, Chapter 6: Glucose Control Levels, page 27. http://www.idf.org/webdata/docs/GGT2D%20...; accessed Aug. 18, 2008

(8) American Diabetes Association, A1C Test, http://www.diabetes.org/type-1-diabetes/a1c-test.jsp; accessed Aug. 7, 2008

    
    Contacts:
    Media                        Investors
    Carmel Hogan                 John Elicker
    Bristol-Myers Squibb         Bristol-Myers Squibb
    Office: +33-1-58-83-65-55    Office: +1-212-546-3775
    Cell: +33-6-74-10-76-58      john.elicker@bms.com
    carmel.hogan@bms.com

    Jim Minnick                  Mina Blair
    AstraZeneca                  AstraZeneca
    Office: +1-302-886-5135      Office: +44-20-7304-5084
    Cell: +1-610-457-1828        mina.blair@astrazeneca.com
    jim.minnick@astrazeneca.com

Contacts: Media - Carmel Hogan, Bristol-Myers Squibb, Office: +33-1-58-83-65-55, Cell: +33-6-74-10-76-58, carmel.hogan@bms.com; Jim Minnick, AstraZeneca, Office: +1-302-886-5135, Cell: +1-610-457-1828, jim.minnick@astrazeneca.com; Investors - John Elicker, Bristol-Myers Squibb, Office: +1-212-546-3775, john.elicker@bms.com; Mina Blair, AstraZeneca, Office: +44-20-7304-5084, mina.blair@astrazeneca.com

Contenido patrocinado